Hodkinson, Alex
Dietz, Kristina Charlotte
Lefebvre, Carol
Golder, Su
Jones, Mark
Doshi, Peter
Heneghan, Carl
Jefferson, Tom
Boutron, Isabelle
Stewart, Lesley
Funding for this research was provided by:
Cochrane methods innovation fund (N/A)
Article History
Received: 8 January 2018
Accepted: 27 June 2018
First Online: 8 August 2018
Ethics approval and consent to participate
: This study was granted ethical approval by the University of York Health Sciences Research Ethics and Integrity Governance Committee on 16 May 2016.
: All authors have completed the ICMJE uniform disclosure.PD received personal fees from European Respiratory Society, grants from UK NIHR, grants from American Association of Colleges of Pharmacy, grants from Cochrane Methods Innovation Fund outside this work; and is also an associate editor of The BMJ and an unpaid member of the IMEDS steering committee at the Reagan-Udall Foundation for the FDA, which focuses on drug safety research.TJ was a recipient of a UK National Institute for Health Research grant for a Cochrane review of neuraminidase inhibitors for influenza. Receives royalties from his books published by Il Pensiero Scientifico Editore, Rome and Blackwells. Is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011-13, TJ acted as an expert witness in litigation related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. He also acted as a consultant for Roche (1997-99), GSK (2001-2), Sanofi-Synthelabo (2003), and IMS Health (2013). TJ is a cosignatory of the Nordic Cochrane Centre Complaint to the European Medicines Agency (EMA) over maladministration at the EMA in relation to the investigation of alleged harms of HPV vaccines and consequent complaints to the European Ombudsman. TJ is co-holder of a John and Laura Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. The authors declare that they have no competing interests except for PD and TJ.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.